Speed of recovery in adult patients with community-acquired pneumonia; moxifloxacin versus levofloxacin
Introduction: To evaluate the speed of recovery in CAP-treated adults with Moxifloxacin versus levofloxacin. Methodology:A retrospective multicenter study between January 14, 2010 - March 23, 2017. Patients' records with the diagnosis of community-acquired pneumonia (CAP), age ≥ 18 and ≤ 60...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Journal of Infection in Developing Countries
2018-10-01
|
| Series: | Journal of Infection in Developing Countries |
| Subjects: | |
| Online Access: | https://jidc.org/index.php/journal/article/view/10335 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850193613924859904 |
|---|---|
| author | Jamal Wadi Al Ramahi Mustafa Ramadan Waad Jaber Lamya Abushanab Mohammad Mughrabi Noor Alshamayleh Ahmad Mulhem Dania Momani Mohammad Obaidat Ghayda Haddad Basma Khalil Anas Zahran Esraa Odat Nadeen Kufoof Haneen Arabiat Amr Diab Antonio Anzueto |
| author_facet | Jamal Wadi Al Ramahi Mustafa Ramadan Waad Jaber Lamya Abushanab Mohammad Mughrabi Noor Alshamayleh Ahmad Mulhem Dania Momani Mohammad Obaidat Ghayda Haddad Basma Khalil Anas Zahran Esraa Odat Nadeen Kufoof Haneen Arabiat Amr Diab Antonio Anzueto |
| author_sort | Jamal Wadi Al Ramahi |
| collection | DOAJ |
| description |
Introduction: To evaluate the speed of recovery in CAP-treated adults with Moxifloxacin versus levofloxacin.
Methodology:A retrospective multicenter study between January 14, 2010 - March 23, 2017. Patients' records with the diagnosis of community-acquired pneumonia (CAP), age ≥ 18 and ≤ 60 years old, susceptible bacteria to the prescribed fluoroquinolone, completed three days of antimicrobial therapy and who were switched from parenteral to the oral form for the same antimicrobial agent were included.
Results: 701 charts were reviewed, 367 were excluded; not on respiratory fluoroquinolones (RFQ), age > 60 or < 18 years old, not enough data, prior antimicrobials, hospital-associated pneumonia, < 3 days of therapy, and one pregnant woman. 334 patients were Included; 167 levofloxacin and 167 moxifloxacin, with 68.5% males (P = 0.259), no significant difference in comorbidities (P > .05), but increased diabetes mellitus in moxifloxacin-treated patients (P = 0.012). No significant difference in Pneumonia Severity Index (PSI). Multivariate and univariate analysis demonstrated that day 3 rate of improvement; levofloxacin-treated patients 75.9% (95% CI, 69.9 to 81.8), and 84.0% (95% CI, 78.1 to 89.9) for Moxifloxacin (difference -8.1%, 95% CI, -16.5 - .003, P = 0.058). And day 5 rates of improvement in Levofloxacin-treated patients was 91.9%, (95% CI, 88.3 – 95.6), and 95.5% (95% CI, 91.8 - 99.2) for moxifloxacin (difference -3.5%, 95% CI, -8.7 - 1.7, P = 0.184). There was no significant difference for patients with radiological diagnoses for day 3 (P = 0.832) and 5 (P = 0.929).
Conclusions: Our uni-and-multivariate analyses demonstrated that moxifloxacin exhibited no significant differences in the rates of improvement on days 3 and 5.
|
| format | Article |
| id | doaj-art-a8456cb13f5e481a895a7a99b44c5d7a |
| institution | OA Journals |
| issn | 1972-2680 |
| language | English |
| publishDate | 2018-10-01 |
| publisher | The Journal of Infection in Developing Countries |
| record_format | Article |
| series | Journal of Infection in Developing Countries |
| spelling | doaj-art-a8456cb13f5e481a895a7a99b44c5d7a2025-08-20T02:14:12ZengThe Journal of Infection in Developing CountriesJournal of Infection in Developing Countries1972-26802018-10-01121010.3855/jidc.10335Speed of recovery in adult patients with community-acquired pneumonia; moxifloxacin versus levofloxacinJamal Wadi Al Ramahi0Mustafa Ramadan1Waad Jaber2Lamya Abushanab3Mohammad Mughrabi4Noor Alshamayleh5Ahmad Mulhem6Dania Momani7Mohammad Obaidat8Ghayda Haddad9Basma Khalil10Anas Zahran11Esraa Odat12Nadeen Kufoof13Haneen Arabiat14Amr Diab15Antonio Anzueto16Al Khalidi Hospital and Medical Center. Amman, JordanAl Takhassusi Hospital, Amman, JordanAl Takhassusi Hospital, Amman, JordanJordan Hospital and Medical Center, Amman, JordanJordan Hospital and Medical Center, Amman, JordanJordan Hospital and Medical Center, Amman, JordanJordan Hospital and Medical Center, Amman, JordanAl Khalidi Hospital and Medical Center. Amman, JordanJordan Hospital and Medical Center, Amman, JordanAl Khalidi Hospital and Medical Center. Amman, JordanAl Takhassusi Hospital, Amman, JordanArab Medical Center, Amman, JordanArab Medical Center, Amman, JordanArab Medical Center, Amman, JordanArab Medical Center, Amman, JordanInternal medicine department. Al Takhassusi HospitalUniversity of Texas Health Science Center, San Antonio, TX, United States Introduction: To evaluate the speed of recovery in CAP-treated adults with Moxifloxacin versus levofloxacin. Methodology:A retrospective multicenter study between January 14, 2010 - March 23, 2017. Patients' records with the diagnosis of community-acquired pneumonia (CAP), age ≥ 18 and ≤ 60 years old, susceptible bacteria to the prescribed fluoroquinolone, completed three days of antimicrobial therapy and who were switched from parenteral to the oral form for the same antimicrobial agent were included. Results: 701 charts were reviewed, 367 were excluded; not on respiratory fluoroquinolones (RFQ), age > 60 or < 18 years old, not enough data, prior antimicrobials, hospital-associated pneumonia, < 3 days of therapy, and one pregnant woman. 334 patients were Included; 167 levofloxacin and 167 moxifloxacin, with 68.5% males (P = 0.259), no significant difference in comorbidities (P > .05), but increased diabetes mellitus in moxifloxacin-treated patients (P = 0.012). No significant difference in Pneumonia Severity Index (PSI). Multivariate and univariate analysis demonstrated that day 3 rate of improvement; levofloxacin-treated patients 75.9% (95% CI, 69.9 to 81.8), and 84.0% (95% CI, 78.1 to 89.9) for Moxifloxacin (difference -8.1%, 95% CI, -16.5 - .003, P = 0.058). And day 5 rates of improvement in Levofloxacin-treated patients was 91.9%, (95% CI, 88.3 – 95.6), and 95.5% (95% CI, 91.8 - 99.2) for moxifloxacin (difference -3.5%, 95% CI, -8.7 - 1.7, P = 0.184). There was no significant difference for patients with radiological diagnoses for day 3 (P = 0.832) and 5 (P = 0.929). Conclusions: Our uni-and-multivariate analyses demonstrated that moxifloxacin exhibited no significant differences in the rates of improvement on days 3 and 5. https://jidc.org/index.php/journal/article/view/10335LevofloxacinMoxifloxacinCAPCommunity-Associated PneumoniaSpeed of Recovery |
| spellingShingle | Jamal Wadi Al Ramahi Mustafa Ramadan Waad Jaber Lamya Abushanab Mohammad Mughrabi Noor Alshamayleh Ahmad Mulhem Dania Momani Mohammad Obaidat Ghayda Haddad Basma Khalil Anas Zahran Esraa Odat Nadeen Kufoof Haneen Arabiat Amr Diab Antonio Anzueto Speed of recovery in adult patients with community-acquired pneumonia; moxifloxacin versus levofloxacin Journal of Infection in Developing Countries Levofloxacin Moxifloxacin CAP Community-Associated Pneumonia Speed of Recovery |
| title | Speed of recovery in adult patients with community-acquired pneumonia; moxifloxacin versus levofloxacin |
| title_full | Speed of recovery in adult patients with community-acquired pneumonia; moxifloxacin versus levofloxacin |
| title_fullStr | Speed of recovery in adult patients with community-acquired pneumonia; moxifloxacin versus levofloxacin |
| title_full_unstemmed | Speed of recovery in adult patients with community-acquired pneumonia; moxifloxacin versus levofloxacin |
| title_short | Speed of recovery in adult patients with community-acquired pneumonia; moxifloxacin versus levofloxacin |
| title_sort | speed of recovery in adult patients with community acquired pneumonia moxifloxacin versus levofloxacin |
| topic | Levofloxacin Moxifloxacin CAP Community-Associated Pneumonia Speed of Recovery |
| url | https://jidc.org/index.php/journal/article/view/10335 |
| work_keys_str_mv | AT jamalwadialramahi speedofrecoveryinadultpatientswithcommunityacquiredpneumoniamoxifloxacinversuslevofloxacin AT mustafaramadan speedofrecoveryinadultpatientswithcommunityacquiredpneumoniamoxifloxacinversuslevofloxacin AT waadjaber speedofrecoveryinadultpatientswithcommunityacquiredpneumoniamoxifloxacinversuslevofloxacin AT lamyaabushanab speedofrecoveryinadultpatientswithcommunityacquiredpneumoniamoxifloxacinversuslevofloxacin AT mohammadmughrabi speedofrecoveryinadultpatientswithcommunityacquiredpneumoniamoxifloxacinversuslevofloxacin AT nooralshamayleh speedofrecoveryinadultpatientswithcommunityacquiredpneumoniamoxifloxacinversuslevofloxacin AT ahmadmulhem speedofrecoveryinadultpatientswithcommunityacquiredpneumoniamoxifloxacinversuslevofloxacin AT daniamomani speedofrecoveryinadultpatientswithcommunityacquiredpneumoniamoxifloxacinversuslevofloxacin AT mohammadobaidat speedofrecoveryinadultpatientswithcommunityacquiredpneumoniamoxifloxacinversuslevofloxacin AT ghaydahaddad speedofrecoveryinadultpatientswithcommunityacquiredpneumoniamoxifloxacinversuslevofloxacin AT basmakhalil speedofrecoveryinadultpatientswithcommunityacquiredpneumoniamoxifloxacinversuslevofloxacin AT anaszahran speedofrecoveryinadultpatientswithcommunityacquiredpneumoniamoxifloxacinversuslevofloxacin AT esraaodat speedofrecoveryinadultpatientswithcommunityacquiredpneumoniamoxifloxacinversuslevofloxacin AT nadeenkufoof speedofrecoveryinadultpatientswithcommunityacquiredpneumoniamoxifloxacinversuslevofloxacin AT haneenarabiat speedofrecoveryinadultpatientswithcommunityacquiredpneumoniamoxifloxacinversuslevofloxacin AT amrdiab speedofrecoveryinadultpatientswithcommunityacquiredpneumoniamoxifloxacinversuslevofloxacin AT antonioanzueto speedofrecoveryinadultpatientswithcommunityacquiredpneumoniamoxifloxacinversuslevofloxacin |